BridgeBio Pharma Management
Management Kriterienprüfungen 0/4
Wichtige Informationen
Neil Kumar
Geschäftsführender
US$12.2m
Gesamtvergütung
Prozentsatz des Geschäftsführergehalts | 6.1% |
Amtszeit als Geschäftsführer | 9.2yrs |
Eigentum des Geschäftsführers | 3.7% |
Durchschnittliche Amtszeit des Managements | 5.4yrs |
Durchschnittliche Amtszeit der Vorstandsmitglieder | 4.4yrs |
Jüngste Management Updates
Recent updates
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing
Jun 10BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)
Jun 03BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck
Jan 11Estimating The Intrinsic Value Of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Nov 06BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing
Jul 02New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)
May 09Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook
Feb 28Analysts Just Made A Major Revision To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts
Jan 09BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status
Oct 11BridgeBio, Sentynl's Nulibry for rare disorder in children gets approval in EU
Sep 20BridgeBio Pharma: Down But Not Out
Aug 31BridgeBio starts dosing in phase 1 trial of BBP-671 for metabolic disorders
Aug 18Industry Analysts Just Upgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts By 33%
Aug 10BridgeBio Pharma GAAP EPS of -$0.07 beats by $0.65, revenue of $73.75M beats by $48.75M
Aug 04BridgeBio, Sentynl's Nulibry get EMA panel nod for approval in EU
Jul 25Analyse der Geschäftsführervergütung
Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$538m |
Dec 31 2023 | US$12m | US$742k | -US$643m |
Sep 30 2023 | n/a | n/a | -US$613m |
Jun 30 2023 | n/a | n/a | -US$573m |
Mar 31 2023 | n/a | n/a | -US$425m |
Dec 31 2022 | US$7m | US$1m | -US$481m |
Sep 30 2022 | n/a | n/a | -US$491m |
Jun 30 2022 | n/a | n/a | -US$509m |
Mar 31 2022 | n/a | n/a | -US$596m |
Dec 31 2021 | US$26m | US$725k | -US$563m |
Sep 30 2021 | n/a | n/a | -US$535m |
Jun 30 2021 | n/a | n/a | -US$495m |
Mar 31 2021 | n/a | n/a | -US$520m |
Dec 31 2020 | US$10m | US$550k | -US$449m |
Sep 30 2020 | n/a | n/a | -US$402m |
Jun 30 2020 | n/a | n/a | -US$346m |
Mar 31 2020 | n/a | n/a | -US$291m |
Dec 31 2019 | US$26m | US$503k | -US$261m |
Sep 30 2019 | n/a | n/a | -US$226m |
Jun 30 2019 | n/a | n/a | -US$197m |
Mar 31 2019 | n/a | n/a | -US$155m |
Dec 31 2018 | US$450k | US$450k | -US$131m |
Geschäftsführer
Neil Kumar (45 yo)
9.2yrs
Amtszeit
US$12,158,626
Vergütung
Dr. Neil Kumar, Ph D., has been Director of Lianbio since October 2019. He is a Co-Founder of BridgeBio Pharma, Inc. and serves as its Chief Executive Officer and Director since April 2015.He serves as Pr...
Führungsteam
Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
---|---|---|---|---|
Co-Founder | 9.2yrs | US$12.16m | 3.69% $ 192.4m | |
Co-Founder | no data | US$1.11m | 0.66% $ 34.3m | |
Co-Founder | no data | US$1.74m | 0.59% $ 30.6m | |
CFO & Secretary | 5.7yrs | US$6.65m | 0.041% $ 2.1m | |
Chairman of Research & Development | 5.4yrs | US$2.01m | keine Daten | |
Chief Scientific Officer | 8.2yrs | US$2.75m | keine Daten | |
Vice President of Communications | no data | keine Daten | keine Daten | |
Chief Scientific Officer of Oncology | 4.5yrs | keine Daten | keine Daten | |
Chief Product Officer | no data | keine Daten | keine Daten | |
Chief Executive Officer of Gene Therapy | no data | keine Daten | keine Daten | |
Chief Commercial Officer | 3.1yrs | keine Daten | keine Daten | |
Chief Regulatory Affairs Officer | 2.4yrs | keine Daten | keine Daten |
5.4yrs
Durchschnittliche Betriebszugehörigkeit
54.5yo
Durchschnittliches Alter
Vorstandsmitglieder
Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
---|---|---|---|---|
Co-Founder | 9.2yrs | US$12.16m | 3.69% $ 192.4m | |
Co-Founder | 5.6yrs | US$1.11m | 0.66% $ 34.3m | |
Co-Founder | less than a year | US$1.74m | 0.59% $ 30.6m | |
Independent Director | 2.8yrs | US$600.00k | 0.010% $ 537.5k | |
Independent Director | 4.3yrs | US$600.00k | 0.0056% $ 289.9k | |
Independent Director | 5.3yrs | US$600.00k | 0% $ 0 | |
Independent Director | 4yrs | US$600.00k | 0.0048% $ 250.8k | |
Independent Director | 8.3yrs | US$600.00k | 0% $ 0 | |
Director | 8.3yrs | US$600.00k | 0.047% $ 2.5m | |
Director | 4.5yrs | US$600.00k | 0.0038% $ 199.2k | |
Independent Director | 4yrs | US$600.00k | 0.14% $ 7.1m | |
Independent Director | 2.8yrs | US$600.00k | 0.0064% $ 334.2k |
4.4yrs
Durchschnittliche Betriebszugehörigkeit
62.5yo